;PMID: 9927037
;source_file_1367.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..36] = [t:0..36]
;1)sentence:[e:41..170] = [t:41..170]
;2)section:[e:174..326] = [t:174..326]
;3)section:[e:330..436] = [t:330..436]
;4)sentence:[e:440..596] = [t:440..596]
;5)sentence:[e:597..776] = [t:597..776]
;6)sentence:[e:777..977] = [t:777..977]
;7)sentence:[e:978..1219] = [t:978..1219]
;8)sentence:[e:1220..1379] = [t:1220..1379]
;9)section:[e:1383..1427] = [t:1383..1427]

;section 0 Span:0..36
;Cancer Res  1999 Jan 15;59(2):307-10
(SEC
  (FRAG (NN:[0..6] Cancer) (NNP:[7..10] Res) (CD:[12..16] 1999)
        (NNP:[17..20] Jan) (CD:[21..27] 15;59-LRB-) (CD:[27..28] 2)
        (-RRB-:[28..29] -RRB-) (CD:[29..33] :307) (NN:[33..34] -)
        (CD:[34..36] 10)))

;sentence 1 Span:41..170
;Somatic mutations in the kinase domain of the Met/hepatocyte growth factor 
;receptor gene in childhood hepatocellular carcinomas.
;[66..72]:gene-protein:"kinase"
;[87..90]:gene-rna:"Met"
;[91..125]:gene-rna:"hepatocyte growth factor  receptor"
;[134..169]:malignancy:"childhood hepatocellular carcinomas"
(SENT
  (NP-HLN
    (NP (JJ:[41..48] Somatic) (NNS:[49..58] mutations))
    (PP (IN:[59..61] in)
      (NP
        (NP (DT:[62..65] the) (NN:[66..72] kinase) (NN:[73..79] domain))
        (PP (IN:[80..82] of)
          (NP (DT:[83..86] the)
            (NML (NN:[87..90] Met) (SYM:[90..91] /) (NN:[91..101] hepatocyte))
            (NML (NN:[102..108] growth) (NN:[109..115] factor)
                 (NN:[117..125] receptor))
            (NN:[126..130] gene)))))
    (PP (IN:[131..133] in)
      (NP (NN:[134..143] childhood) (JJ:[144..158] hepatocellular)
          (NNS:[159..169] carcinomas)))
    (.:[169..170] .)))

;section 2 Span:174..326
;Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee
; KS, Lee SH, Yoo NJ, Jang JJ, Pack S, Zhuang Z, Schmidt L, Zbar B, Lee JY.
(SEC
  (FRAG (NNP:[174..178] Park) (NNP:[179..181] WS) (,:[181..182] ,)
        (NNP:[183..187] Dong) (NNP:[188..190] SM) (,:[190..191] ,)
        (NNP:[192..195] Kim) (NNP:[196..198] SY) (,:[198..199] ,)
        (NNP:[200..202] Na) (NNP:[203..205] EY) (,:[205..206] ,)
        (NNP:[207..211] Shin) (NNP:[212..214] MS) (,:[214..215] ,)
        (NNP:[216..218] Pi) (NNP:[219..221] JH) (,:[221..222] ,)
        (NNP:[223..226] Kim) (NNP:[227..229] BJ) (,:[229..230] ,)
        (NNP:[231..234] Bae) (NNP:[235..237] JH) (,:[237..238] ,)
        (NNP:[239..243] Hong) (NNP:[244..246] YK) (,:[246..247] ,)
        (NNP:[248..251] Lee) (NNP:[253..255] KS) (,:[255..256] ,)
        (NNP:[257..260] Lee) (NNP:[261..263] SH) (,:[263..264] ,)
        (NNP:[265..268] Yoo) (NNP:[269..271] NJ) (,:[271..272] ,)
        (NNP:[273..277] Jang) (NNP:[278..280] JJ) (,:[280..281] ,)
        (NNP:[282..286] Pack) (NNP:[287..289] S,) (NNP:[290..296] Zhuang)
        (NNP:[297..298] Z) (,:[298..299] ,) (NNP:[300..307] Schmidt)
        (NNP:[308..310] L,) (NNP:[311..315] Zbar) (NNP:[316..317] B)
        (,:[317..318] ,) (NNP:[319..322] Lee) (NNP:[323..325] JY)
        (.:[325..326] .)))

;section 3 Span:330..436
;Department of Pathology and Cancer Research Institute, Catholic University 
;Medical College, Seoul, Korea.
(SEC
  (FRAG (NNP:[330..340] Department) (IN:[341..343] of)
        (NNP:[344..353] Pathology) (CC:[354..357] and) (NNP:[358..364] Cancer)
        (NNP:[365..373] Research) (NNP:[374..383] Institute) (IN:[383..384] ,)
        (NNP:[385..393] Catholic) (NNP:[394..404] University)
        (NNP:[406..413] Medical) (NNP:[414..421] College) (,:[421..422] ,)
        (NNP:[423..428] Seoul) (,:[428..429] ,) (NNP:[430..435] Korea)
        (.:[435..436] .)))

;sentence 4 Span:440..596
;The MET protooncogene encodes a transmembrane tyrosine kinase identified as
;the  receptor of a polypeptide known as hepatocyte growth factor/scatter
;factor.
;[444..447]:gene-rna:"MET"
;[486..501]:gene-protein:"tyrosine kinase"
;[556..580]:gene-protein:"hepatocyte growth factor"
;[581..595]:gene-protein:"scatter factor"
(SENT
  (S
    (NP-SBJ (DT:[440..443] The) (NN:[444..447] MET)
            (NN:[448..461] protooncogene))
    (VP (VBZ:[462..469] encodes)
      (NP
        (NP (DT:[470..471] a) (JJ:[472..485] transmembrane)
           (NN:[486..494] tyrosine) (NN:[495..501] kinase))
        (VP (VBN:[502..512] identified)
          (NP (-NONE-:[512..512] *))
          (PP (IN:[513..515] as)
            (NP
              (NP (DT:[516..519] the) (NN:[521..529] receptor))
              (PP (IN:[530..532] of)
                (NP
                  (NP (DT:[533..534] a) (NN:[535..546] polypeptide))
                  (VP (VBN:[547..552] known)
                    (NP (-NONE-:[552..552] *))
                    (PP (IN:[553..555] as)
                      (NP
                        (NML (NN:[556..566] hepatocyte) (NN:[567..573] growth)
                             (NN:[574..580] factor))
                        (SYM:[580..581] /)
                        (NML (NN:[581..588] scatter) (NN:[589..595] factor))))))))))))
    (.:[595..596] .)))

;sentence 5 Span:597..776
;We  performed PCR-based single-strand conformational polymorphism and
;sequencing  analysis of the tyrosine kinase domain of the MET gene (exon
;15-19) in 75  primary liver cancers.
;[695..710]:gene-protein:"tyrosine kinase"
;[725..728]:gene-rna:"MET"
;[735..745]:variation-location:"exon 15-19"
;[754..775]:malignancy:"primary liver cancers"
(SENT
  (S
    (NP-SBJ (PRP:[597..599] We))
    (VP (VBD:[601..610] performed)
      (NP
        (NP
          (ADJP (NN:[611..614] PCR) (HYPH:[614..615] -) (VBN:[615..620] based))
          (NML (JJ:[621..627] single) (HYPH:[627..628] -) (NN:[628..634] strand))
          (JJ:[635..649] conformational) (NN:[650..662] polymorphism))
        (CC:[663..666] and)
        (NP
          (NP (NN:[667..677] sequencing) (NN:[679..687] analysis))
          (PP (IN:[688..690] of)
            (NP
              (NP (DT:[691..694] the)
                 (NN:[695..703] tyrosine) (NN:[704..710] kinase)
                (NN:[711..717] domain))
              (PP (IN:[718..720] of)
                (NP (DT:[721..724] the) (NN:[725..728] MET) (NN:[729..733] gene)))
              (PRN (-LRB-:[734..735] -LRB-)
                (NP
                  (NP
                    (NML-1 (NN:[735..739] exon))
                    (CD:[740..742] 15))
                  (PP (HYPH:[742..743] -)
                    (NP
                      (NML-1 (-NONE-:[743..743] *P*))
                      (CD:[743..745] 19))))
                (-RRB-:[745..746] -RRB-))))))
      (PP-LOC (IN:[747..749] in)
        (NP (CD:[750..752] 75)
           (JJ:[754..761] primary) (NN:[762..767] liver)
           (NNS:[768..775] cancers))))
    (.:[775..776] .)))

;sentence 6 Span:777..977
;Three missense mutations were detected exclusively in 10  childhood
;hepatocellular carcinomas (HCCs), while no mutations were detected in  16
;adult HCCs, 21 cholangiocarcinomas, or 28 hepatoblastomas.
;[783..801]:variation-type:"missense mutations"
;[835..870]:malignancy:"childhood hepatocellular carcinomas"
;[872..876]:malignancy:"HCCs"
;[919..929]:malignancy:"adult HCCs"
;[934..953]:malignancy:"cholangiocarcinomas"
;[961..976]:malignancy:"hepatoblastomas"
(SENT
  (S
    (NP-SBJ-1 (CD:[777..782] Three)
       (JJ:[783..791] missense) (NNS:[792..801] mutations))
    (VP (VBD:[802..806] were)
      (VP (VBN:[807..815] detected)
        (NP-1 (-NONE-:[815..815] *))
        (ADVP (RB:[816..827] exclusively))
        (PP (IN:[828..830] in)
          (NP (CD:[831..833] 10) (NN:[835..844] childhood)
            (NML
              (NML (JJ:[845..859] hepatocellular) (NNS:[860..870] carcinomas))
              (NML (-LRB-:[871..872] -LRB-) (NNS:[872..876] HCCs)
                   (-RRB-:[876..877] -RRB-)))))
        (,:[877..878] ,)
        (SBAR-ADV (IN:[879..884] while)
          (S
            (NP-SBJ-2 (DT:[885..887] no) (NNS:[888..897] mutations))
            (VP (VBD:[898..902] were)
              (VP (VBN:[903..911] detected)
                (NP-2 (-NONE-:[911..911] *))
                (PP-LOC (IN:[912..914] in)
                  (NP
                    (NP (CD:[916..918] 16)
                       (JJ:[919..924] adult) (NNS:[925..929] HCCs))
                    (,:[929..930] ,)
                    (NP (CD:[931..933] 21) (NNS:[934..953] cholangiocarcinomas))
                    (,:[953..954] ,) (CC:[955..957] or)
                    (NP (CD:[958..960] 28) (NNS:[961..976] hepatoblastomas))))))))))
    (.:[976..977] .)))

;sentence 7 Span:978..1219
;The extremely  short incubation period from hepatitis B virus infection to
;the genesis of  childhood HCC as compared with the adult HCC suggests that
;there may be an  additional mechanism that accelerates the carcinogenesis of
;childhood HCC.
;[1022..1049]:malignancy:"hepatitis B virus infection"
;[1069..1082]:malignancy:"childhood HCC"
;[1104..1113]:malignancy:"adult HCC"
;[1205..1218]:malignancy:"childhood HCC"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (DT:[978..981] The)
          (ADJP (RB:[982..991] extremely) (JJ:[993..998] short))
          (NN:[999..1009] incubation) (NN:[1010..1016] period))
        (PP (IN:[1017..1021] from)
          (NP
            (NML (NN:[1022..1031] hepatitis) (NN:[1032..1033] B))
            (NN:[1034..1039] virus) (NN:[1040..1049] infection)))
        (PP (TO:[1050..1052] to)
          (NP
            (NP (DT:[1053..1056] the) (NN:[1057..1064] genesis))
            (PP (IN:[1065..1067] of)
              (NP (NN:[1069..1078] childhood) (NN:[1079..1082] HCC))))))
      (SBAR (IN:[1083..1085] as)
        (S
          (NP-SBJ-2 (-NONE-:[1085..1085] *))
          (VP (VBN:[1086..1094] compared)
            (NP-2 (-NONE-:[1094..1094] *))
            (PP-CLR (IN:[1095..1099] with)
              (NP (DT:[1100..1103] the)
                 (JJ:[1104..1109] adult) (NN:[1110..1113] HCC)))))))
    (VP (VBZ:[1114..1122] suggests)
      (SBAR (IN:[1123..1127] that)
        (S
          (NP-SBJ (EX:[1128..1133] there))
          (VP (MD:[1134..1137] may)
            (VP (VB:[1138..1140] be)
              (NP-PRD
                (NP (DT:[1141..1143] an) (JJ:[1145..1155] additional)
                    (NN:[1156..1165] mechanism))
                (SBAR
                  (WHNP-1 (WDT:[1166..1170] that))
                  (S
                    (NP-SBJ-1 (-NONE-:[1170..1170] *T*))
                    (VP (VBZ:[1171..1182] accelerates)
                      (NP
                        (NP (DT:[1183..1186] the)
                            (NN:[1187..1201] carcinogenesis))
                        (PP (IN:[1202..1204] of)
                          (NP (NN:[1205..1214] childhood) (NN:[1215..1218] HCC)))))))))))))
    (.:[1218..1219] .)))

;sentence 8 Span:1220..1379
;Our  results indicate that mutations of the tyrosine kinase domain of the MET
;gene  may be involved in the acceleration of the carcinogenesis in childhood
;HCC.
;[1264..1279]:gene-protein:"tyrosine kinase"
;[1294..1297]:gene-rna:"MET"
;[1365..1378]:malignancy:"childhood HCC"
(SENT
  (S
    (NP-SBJ (PRP$:[1220..1223] Our) (NNS:[1225..1232] results))
    (VP (VBP:[1233..1241] indicate)
      (SBAR (IN:[1242..1246] that)
        (S
          (NP-SBJ-1
            (NP (NNS:[1247..1256] mutations))
            (PP (IN:[1257..1259] of)
              (NP
                (NP (DT:[1260..1263] the)
                   (NN:[1264..1272] tyrosine) (NN:[1273..1279] kinase)
                  (NN:[1280..1286] domain))
                (PP (IN:[1287..1289] of)
                  (NP (DT:[1290..1293] the) (NN:[1294..1297] MET)
                      (NN:[1298..1302] gene))))))
          (VP (MD:[1304..1307] may)
            (VP (VB:[1308..1310] be)
              (VP (VBN:[1311..1319] involved)
                (NP-1 (-NONE-:[1319..1319] *))
                (PP-CLR (IN:[1320..1322] in)
                  (NP
                    (NP (DT:[1323..1326] the) (NN:[1327..1339] acceleration))
                    (PP (IN:[1340..1342] of)
                      (NP (DT:[1343..1346] the) (NN:[1347..1361] carcinogenesis)))
                    (PP (IN:[1362..1364] in)
                      (NP (NN:[1365..1374] childhood) (NN:[1375..1378] HCC)))))))))))
    (.:[1378..1379] .)))

;section 9 Span:1383..1427
;PMID: 9927037 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1383..1387] PMID) (::[1387..1388] :) (CD:[1389..1396] 9927037)
        (-LRB-:[1397..1398] -LSB-) (NNP:[1398..1404] PubMed)
        (HYPH:[1405..1406] -) (NN:[1407..1414] indexed) (IN:[1415..1418] for)
        (NNP:[1419..1426] MEDLINE) (-RRB-:[1426..1427] -RSB-)))
